A Candida albicans petite mutant strain with uncoupled oxidative phosphorylation overexpresses MDR1 and has diminished susceptibility to fluconazole and voriconazole

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 5, 2007, Pages 1855-1858

  Cheng, Shaoji ^a   Clancy, Cornelius J ^a,b   Nguyen, Katherine T ^a   Clapp, William ^a,b   Nguyen, M Hong ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; VORICONAZOLE;

ARTICLE; CANDIDA ALBICANS; FUNGAL STRAIN; FUNGUS MUTANT; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS; MUTATION; OXIDATIVE PHOSPHORYLATION; P-GLYCOPROTEIN; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIAZOLES;

EID: 34248398758     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00182-07     Document Type: Article

References (42)

1. Bouchara, J.-P., R. Zouhair, S. L. Boudouil, G. F. R. Renier, D. Chabasse, J.-N. Hallet, and A. Defonatine. 2000. In-vivo selection of an azole-resistant petite mutant of Candida glabrata. J. Med. Microbiol. 49:977-984.
2. Brun, S., C. Aubry, O. Lima, R. Filmon, T. Berges, D. Chabasse, and J. P. Bouchara. 2003. Relationships between respiration and susceptability to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 47: 847-853.
3. Brun, S., T. Berges, P. Poupard, C. Vauzelle-Moreau, D. Chabasse, and J.-P. Bouchara. 2004. Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob. Agents Chemother. 48:1788-1796.
4. Brun, S., F. Dalle, P. Saulnier, G. Renier, A. Bonnin, D. Chabasse, and J. P. Bouchara. 2005. Biological consequences of petite mutations in Candida glabrata. J. Antimicrob. Chemother. 56:307-314.
5. Calabrese, D., J. Bille, and D. Sanglard. 2000. A novel multidrug efflux transporter gene of the major facilitator superfamily from Candida albicans (FLU1) conferring resistance to fluconazole. Microbiology 146:2743-2754.
6. Chau, A. S., C. A. Mendrick, F. J. Sabatelli, D. Loebenberg, and P. M. McNicholas. 2004. Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles. Antimicrob. Agents Chemother. 48:2124-2131.
7. Cheng, S., C. J. Clancy, Z. Zhang, B. Hao, W. Wang, K. A. Iczkowski, M. A. Pfaller, and M. H. Nguyen. 2007. Uncoupling of oxidative phosphorylation enables Candida albicans to resist killing by phagocytes and persist in tissue. Cell. Microbiol. 9:492-501.
8. Clancy, C. J., H. Huang, S. Cheng, H. Derendorf, and M. H. Nguyen. 2006. Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob. Agents Chemother. 50:2569-2572.
9. Defontaine, A., J. P. Bouchara, P. Declerk, C. Planchenault, D. Chabasse, and J. N. Hallet. 1999. In-vitro resistance to azoles associated with mitochondrial DNA deficiency in Candida glabrata. J. Med. Microbiol. 48:663-670.
10. Dominique, I. F. M., and M. B. Jacques. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 134:405-416.
11. Forche, A., G. May, and P. T. Magee. 2005. Demonstration of loss of heterozygosity by single-nucleotide polymorphism microarray analysis and alterations in strain morphology in Candida albicans strains during infection. Eukaryot. Cell 4:156-165.
12. Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morshhauser. 1998. Multiple molecular mechanisms contribute to a step-wise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother. 42:3065-3072.
13. Geraghty, P., and K. Kavanagh. 2003. Erythromycin, an inhibitor of mitoribosomal protein biosynthesis, alters the amphotericin B susceptibility of Candida albicans. J. Pharm. Pharmocol. 55:179-184.
14. Geraghty, P., and K. Kavanagh. 2003. Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B. Arch. Microbiol. 179:295-300.
15. Gupta, V., K., K. Avmeet, P. Shankarling, A. Neeti, S. Panwar, and R. Prasad. 1998. Identification of polymorphic mutant alleles of CaMDR1, a major facilitator of Candida albicans which confers multidrug resistance, and its in vitro transcriptional activation. Curr. Genet. 34:192-199.
16. Henry, K. W., J. T. Nickels, and T. D. Edlind. 2000. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 44:2693-2700.
17. Hiller, D., D. Sanglard, and J. Morschhauser. 2006. Overexpression of the MDR1 gene is sufficient to confer increased resistance to toxic compounds in Candida alibicans. Antimicrob. Agents Chemother. 50:1365-1371.
18. Holmes, A. R., S. Tsao, S. W. Ong, E. Lampling, K. Niimi, M. C. Monk, M. Niimi, A. Kaneko, B. R. Holland, J. Schmid, and R. D. Cannon. 2006. Heterozygosity and functional allelic variation in the Candida albicans efflux pump genes CDR1 and CDR2. Mol. Microbiol. 62:170-186.
19. Kelly, S. L., D. C. Lamb, D. E. Kelly, J. Loeffler, and H. Einsele. 1996. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet 348:1523-1524.
20. Kelly, S. L., D. C. Lamb, D. E. Kelly, N. J. Manning, J. Loeffler, and H. Hebart. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation. FEBS Lett. 400:80-82.
21. Marichal, P., L. Koymans, S. Willemsens, D. Bellens, P. Verhasselt, W. Luyten, M. Borgers, F. C. S. Ramaekers, F. C. Odds, and H. V. Bossche. 1999. Contribution of mutations in the cytochrome P450 14 α-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology 145:2701-2713.
22. Miyazaki, T., Y. Miyazaki, K. Izumikawa, H. Kakeya, S. Miyakoshi, J. E. Bennett, and S. Kohno. 2006. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob. Agents Chemother. 50:580-586.
23. Morschhauser, J. 2002. The genetic basis of fluconazole resistance development in Candida albicans. Biochim. Biophys. Acta 1587:240-248.
24. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
25. Niewerth, M., D. Kunze, M. Seibold, M. Schaller, H. C. Korting, and B. Hube. 2003. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob. Agents Chemother. 47:1805-1817.
26. Niimi, K., K. Maki, F. Ikeda, A. R. Holmes, E. Lamping, M. Niimi, B. C. Monk, and R. D. Cannon. 2006. Overexpression of Candida alibicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibilty. Antimicrob. Agents Chemother. 50:1148-1155.
27. Nolte, F. S., T. Parkinson, D. J. Falconer, S. Dix, J. Williams, C. Gilmore, R. Geller, and J. R. Wingard. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 41:196-199.
28. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
29. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
30. Sanglard, D., K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. 39:2378-2386.
31. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilites of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
32. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 143: 405-416.
33. Sanglard, D., F. Ischer, L. Koymans, and J. Bille. 1997. Amino acid substitutions in the cytochrome P-450 lanosterol 14 α-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to antifungal agents. Antimicrob. Agents Chemother. 42:241-253.
34. Sanglard, D., F. Ischer, and J. Bille. 2001. Role of ATP-binding cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob. Agents Chemother. 45:1174-1183.
35. Schaller, M., W. Schafer, H. C Korting, and B. Hube. 1998. Differential expression of secreted aspartyl proteinases in a model of human oral candidiasis and in patient samples from the oral cavity. Mol. Microbiol. 29:605-615.
36. Selmecki, A., A. Forcher, and J. Berman. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367-369.
37. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
38. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-401
39. White, T. C., S. Holleman, F. Dy, L. F. Mirels, and D. A. Stevens. 2002. Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob. Agents Chemother. 46:1704-1713.
40. Wirsching, S., S. Michel, and J. Morschhauser. 2000. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol. Microbiol. 36:856-865.
41. Wirsching, S., S. Michel, G. Kohler, and J. Morschhauser. 2000. Activation of the multiple drug resistance gene MDR1 in fluconazole-resistant, clinical Candida albicans strains is caused by mutations in a trans-regulatory factor. J. Bacteriol. 182:400-404.
42. Yang, Y.-L., and J.-L. Lo. 2001. Mechanisms of antifungal agent resistance. J. Microbiol. Immunol. Infect. 34:79-86.